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ABSTRACT: Dyslipidemia, reduced omega-3 and -6 fatty acids and antioxidative nutrients are modulatory risk factors associated 
with dementia. Diet, genetics and environment interact with nutritional metabolism and susceptibility to neurodegeneration. 
This study investigated the relationship between erythrocyte fatty acids and selected antioxidant nutrients in elderly Nigerians 
with vascular dementia (VD) and Alzheimer’s disease (AD). Forty VD (69.03±8.19 years) twenty AD (71.06±5.0 years) and forty 
control (67.5±6.8 years) subjects were studied. Anthropometric indices, blood pressure (BP) and body mass index (BMI) were 
measured in all subjects. Venous blood sample was drawn from all subjects and erythrocytes separated for the determination of 
fatty acids. Plasma lipids, selenium and vitamin E levels were also measured. There were no differences in BMI, weight and height 
among the three groups except for systolic BP that was lower in VD (148.3±41.8mmHg) than AD (156±36mmHg). Docosahexanoic 
acid and eicosapentanoic acid were lower in VD (6.3±2.2 and 2.0±1.6% total fatty acids [TFA]) and AD (5.4±3.1 and 3.0±1.7 %TFA) 
respectively than in controls (8.9±3.8 and 6.0±4.7%TFA). No variation was recorded in linolenic and arachidonic acids. Significant 
increases in triglycerides, LDL-cholesterol and decreased HDL-cholesterol were observed in both VD and AD when compared to 
controls (p<0.05 in all cases). Plasma selenium levels were significantly decreased in VD and AD than in controls. Eicosapentanoic 
and linolenic acids concentrations were negatively correlated with plasma total cholesterol. Low levels of erythrocyte omega-3 
fatty acids and plasma selenium concentrations are associated with occurrence of vascular dementia and Alzheimer’s disease in 
elderly Nigerians. 
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INTRODUCTION 
Low dietary intake and plasma concentration of omega-3 
polyunsaturated fatty acids (PUFA) are associated with cognitive 
decline and dementia risk1. The etiology of sporadic Alzheimer’s 
disease (AD) is multifactorial. In Yorubas of African descent, it was 
observed that age, genetic variations, cultural, lifestyle and 
environmental factors like habitual diet may play important roles 
in the neurological disorder 2, 3. It was hypothesized that very long 
chain omega-3 PUFA as present in fish oil could be responsible for 
interindividual variation in the rate of decline cognitive 
performance over time in the general elderly population4. Kalmijn 
et al.5 reported that increased docosahexanoic acid (DHA) intake 
was protective of cognitive decline and that low concentration of 
DHA was found in brain tissue of persons with AD. 
Brain cholesterol alters the degradation of amyloid precursor 
protein, which contributes to the pathogenesis of AD. Some 
workers suggested that reduced cellular cholesterol levels promote 
tau phosphorylation in neurons, inhibit dendrite outgrowth and 
synaptogenesis, and induce neurodegeneration6. The gene coding 
for the low-density lipoprotein receptor-related protein gene, 
which is the ApoE receptor and resides on chromosome 12, may be 
associated with the expression of late-onset AD7. 
Lipoproteins are targets for oxidation. It was reported that 
cholesterol oxidation in the brain is of relevance in pathogenesis of 
vascular dementia (VD) cases with mixed pathology 8. Long chain 
PUFAs in brain include both omega-3 (e.g DHA, 22:6n-3) and 
omega-6 (e.g arachidonic acid (AA), 20:6n-6) PUFAs. They are 
prone to free radical attack and hydrogen abstraction leading to 
oxidative damage 9. Oxidative damage in the form of lipid 
peroxidation is known to play a significant role in pathogenesis of 
neurodegeneration in AD 10. Laboratory studies show that markers 
of oxidative damage are elevated in early AD11 and this is associated 
with lower plasma antioxidant levels11.  
When there is a weakening of antioxidant defence or excessive 
production of free radicals, a state of oxidative stress occurs, if 
uncontrolled, these free radicals damage different biological targets 
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such as lipids 12. Lipophilic antioxidants such as vitamin E is 
neuroprotective, essential for normal brain function, accumulates 
in the brain and decrease peroxidation of brain lipids in animal 
models 13,14. Evidence suggests that decreased levels of antioxidant 
vitamins lead to higher susceptibility to oxidative stress and a 
higher grade of low–density lipoprotein (LDL) cholesterol 
oxidation as found in VD patients6. Epidemiological studies 
support antioxidant intake as a means of reducing AD risk from 
oxidative damage.15, 16 
In humans, selenium deficiency has been implicated in etiology 
of cardiovascular disease and conditions in which oxidative stress 
and inflammation are prominent features 17. Selenium deficiency 
also interferes with normal conversion of alpha-linolenic acid 
(ALA) to eicosapentanoic acid (EPA) and DHA leading to 
increased omega 6: omega 3 PUFA ratios 18. Glutathione peroxidase 
(a selenium containing enzyme) and vitamin E inactivates the 
damaging effects of intermediates of lipofuscin metabolism 19. 
Lipofuscin is formed by reactions of hydrogen peroxide with PUFA 
resulting in formation of organic free radicals which could damage 
neuronal DNA. This may have a direct toxic effect on brain cells 19. 
This study is aimed at studying the relationship between omega-3, 
-6 fatty acids and selected antioxidant nutrients in elderly 
Nigerians with vascular dementia (VD) and Alzheimer’s disease in 
comparison to controls. 
MATERIALS AND METHODS 
Study population 
One hundred subjects (60 males, 40 females; mean age: 
65.6±6.71 years) were enrolled in this study. These comprised of: 
- Forty patients (24 males, 16 females; 69.03±8.19 years) attending 
the Neurology clinic at the Medical Outpatient Unit of the 
University College Hospital, Ibadan were diagnosed as suffering 
from vascular dementia using the National Institute of 
Neurological Disorders and Stroke (NINDS) criteria which 
includes incidence of cerebrovascular disease with or without 
history of stroke, onset of dementia within 3 months following a 
recognized stroke and abrupt or fluctuating deterioration in 
cognitive functions 20. Diagnosis by the Consultant Neurologist 
also included taking a medical history, performing a physical and 
neurological examination, and administering a neuropsychological 
battery using Mini-Mental State Examination (MMSE). 
- Twenty patients (9 males, 11 females: mean age: 71.06 ±5.0 years) 
suffering from Alzheimer’s disease were diagnosed using the  
National Institute of Neurological and Cognitive Disorders 
(NINCD) and Stroke/Alzheimer’s Disease and Related Disorders 
Association (ADRDA) criteria. These include: dementia 
established by examination and objective testing, deficits in 2 or 
more cognitive areas, progressive worsening of memory and other 
cognitive functions, onset between ages 40 and 90 years and 
establishment of absence of systemic disorders or other brain 
diseases 21. 
- Forty apparently healthy subjects (27 males, 13 females; mean age: 
67.5 ± 6.83 years) who had no report of endocrine diseases, diabetes 
mellitus, hyperlipidemia or hypertension  and had not used any 
medications or drugs influencing fat metabolism during the last 3 
months before commencement of the study were selected as 
controls. 
Each participant underwent an interview with the aid of a 
structured questionnaire of general health and detailed dietary 
habits using a food frequency questionnaire followed by a standard 
assessment of alcohol and fish consumption during the preceding 3 
months. All the subjects gave their informed consent prior to 
participation in the study. The study was approved by the 
University of Ibadan / University College Hospital Ethical Review 
Committee. Inclusion criteria: Patients with VD and AD and that 
are over 60 years old. Exclusion criteria: Individuals that use 
psychotropic drugs or consume alcohol on a regular basis, and also 
individuals below 60 years old; Unwillingness to participate in the 
study. 
Blood sample collection 
Blood sample (10 ml) was drawn by venipuncture after 10-14 
hours fast and was carefully dispensed into 
ethylenediaminetetraacetic acid (EDTA)-containing bottles. 
Samples were immediately placed on ice before centrifugation. 
Whole blood was centrifuged at 4OC for 10 min at 2500rpm; the 
plasma was immediately separated from erythrocytes, and then 
freshly frozen under nitrogen at -800C, not later than 30 min after 
puncture.The erythrocytes were washed four times at 4OC and 
centrifuged at 2500rpm for 10min. The plasma and buffy coat were 
removed after centrifugation. This procedure was done twice, 
leaving a substantially hemoglobin-free pellet of erythrocyte 
membranes, which was resuspended in twice its volume of 
phosphate buffer saline and stored at -70OC until analyzed for fatty 
acids. The separated plasma sample was used for α-tocopherol, 
selenium and lipid analysis. 
Plasma lipids and fatty acid analysis 
Plasma total cholesterol (TC), triglycerides (TG), and high-
density lipoprotein (HDL) cholesterol were quantified by 
commercially available enzymatic kits (Boehringer Mannheim, 
Mannheim, Germany). LDL- cholesterol was calculated using the 
Friedewald formular (LDL-C: TC - TG/5 - HDL-C). Erythrocyte 
fatty acids were determined using the method of Pandey et al 44 . 
Fatty acid methyl esters (FAMEs) were prepared by methylating 
free fatty acids with methanol sulphuric acid. High Performance 
Liquid Chromatography was carried out using Waters 616/626 LC 
chromatograph equipped with Waters 501 pump solvent 
programmer and Waters UV detector. Absorbance was measured 
@ 300nm. A 90cm x 0.64cm: bondapak C18 column was used with 
acetonitrite (8:20v/v) as eluent at a flow rate of 0.50ml/min. 
FAMEs were identified by comparison with internal standard 
(C17:0). Peak retention times for total fatty acids (TFA) were 
identified by injecting known standards. FAMEs from C12:0 
through C22:6 were expressed as percent TFA.  Precision of fatty 
acids measurement was determined by repeat analysis of a pooled 
plasma sample; 1 pooled plasma sample was assayed for every 20 
samples. 
Measurement of α-tocopherol and selenium 
α-Tocopherol was determined as a major form of vitamin E in 
plasma and was quantified by reversed-phase high-performance 
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liquid chromatography (HPLC) with electrochemical detection as 
previously described 22. Plasma selenium was estimated using 
atomic absorption spectrophotometry. 
Statistical analysis 
Lipid levels, erythrocyte fatty acids content and other potential 
risk factors were compared among VD, AD and non-demented 
subjects using SPSS version 14.0. Data are reported as mean ± 
standard deviation (SD). Means were compared by analysis of 
variance; Chi-square test was used for categorical data while the 
relationships between variables were determined using Pearson 
correlation coefficient. Statistical significance was defined as p < 
0.05. 
Other measurements 
Anthropometric indices were measured which included weight 
in light clothing with shoes off using analogue bathroom scale, and 
height using standiometre. Body mass index (BMI) was computed 
as weight (kg)/height (m2). Subjects were considered as smokers 
(current or past) at the time of blood sampling. Percentage alcohol 
intake was considered as ≥ 2 drinks per day (1 drink was defined as 
13ml alcohol). High blood pressure was defined as systolic blood 
pressure (BP) ≥140mmHg or a diastolic BP ≥ 80mmHg 23. Subjects 
with high BP by this definition or those taking antihypertensive 
medication such as β-blockers, calcium antagonists or diuretics 
were considered hypertensive 24. 
RESULTS 
General characteristics of patients and controls are displayed 
in Table 1. No significant differences in age, BMI and diastolic 
blood pressure were seen in VD and AD patients but increase in 
systolic BP was significant in AD compared with VD patients. The 
percentage consumption of fish in VD and AD was similar and 
higher than controls. Approximately 62.5% of VD and 25% of AD 
patients were hypertensive. 
TABLE 1 General characteristic of VD, AD and control subjects 
Parameters VD (n=40) AD (n=20) Control 
(n=40) 
BMI(kg/m2) 26.4±3.4 26.1±2.6 25.9±2.7 











23 22 18 
Fish intake 
(%)*  
20 20 25 
SBP(mmHg) 148.3±41.8 156±36.0 141±24.2† 
DBP(mmHg) 85.3±20.9 89±18.0 81±15.1 
MMSE Score 12.3±2.2 12.0±3.4 26.1±2.2§ 
*1mg/d = 1.05 fish servings/week 25; † p<0.05 vs VD and AD; § 
p<0.05 vs VD and AD. SBP – systolic blood pressure; DBP – 
diastolic blood pressure 
 
From Table 2, differences in mean plasma TG, LDL-C and 
HDL-C in all patients were significant compared to control. In 
contrast, there was no significant change in the mean plasma total 
cholesterol in the patients and control group. In VD patients, mean 
values of TG and LDL-C were significantly higher and HDL-C 
lower (p<0.05 in all cases) than in AD. The mean percentage 
contributions of n-6 PUFAs: AA and linolenic acid (LA) showed 
minimal variations between the dementia subtypes and control 
subjects. Mean contributions of DHA and EPA were significantly 
lower in the patients than the values in controls. When patients 
with VD and AD as well as control subjects were compared 
according to their mean values of plasma vitamin E and selenium, 
plasma selenium concentration was higher in patients compared to 
controls but changes in vitamin E among the different groups were 
not significant (Table 3). 
TABLE 2 Plasma lipids and erythrocyte fatty acids contents in 
VD, AD and control subjects 
 VD (n=40) AD (n=20) Control 
(n=40) 
TC (mmol/l) 4.3±28.4 4.0±27.2 3.54±26.2 
TG (mmol/l) 3.24±41.9 2.85±36.1 1.80± 26.3* 
HDL-C (mmol/l) 1.03 ± 20.4 1.40 ±14.8 1.60 ± 14.9** 
LDL-C (mmol/l) 2.80±32.4 2.21 ±20.2 1.58 ± 21.1** 
TFA (mmol/l) 37±2.9 35.1±3.1 39.2±2.7 
AA (% TFA) 13.6±2.4 14.0±2.3 14.3 ±3.5 
LA (% TFA) 10.1±2.5 10.3±2.4 8.1 ± 3.3 
DHA (% TFA) 6.3±2.2 5.4±3.1 8.9 ± 3.8# 
EPA (% TFA) 2.0±1.6 3.0±1.7 6.0 ± 4.7# 
*p<0.05  vs VD and AD, **p=0.000 vs VD and AD, # p=0.002 vs VD 
and AD. 
 
In order to ascertain possible relationships among the 
biochemical parameters analyzed in both dementia subtypes with 
the exclusion of control  subjects, Pearson correlation coefficient 
showed that in VD patients, consistent positive correlations were 
present between triglyceride and total cholesterol, LDL cholesterol  
and total cholesterol and LDL cholesterol and triglyceride. On the 
other hand, there were negative correlations between EPA and 
total cholesterol and LA and total cholesterol (Table 4). In AD 
patients, there were no significant correlations among the 
parameters analyzed (data not shown). 
DISCUSSION 
The primary purpose of the present study was to identify 
possible relations between the expression of specific putative 
atherogenic risk modulating factors, antioxidative nutrients and 
the incidence of dementia in this community. In the present study 
the patients were a mixed population of elderly male and female 
adults suffering from either vascular dementia or Alzheimer’s 
disease. Lifestyle factors including habitual diet, cigarette smoking 
and alcohol intake are believed to be major contributors to the 
development of VD and AD. The findings in this study showed that 
a larger percentage of VD (29%) and AD (11.1%) patients were 
either current smokers or had smoked before when compared with 
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control subjects (2.6%). In a review of risk factors and post stroke 
dementia by Pasquier et al 26, it was postulated that cigarette 
smoking was a common risk factor for both Alzheimer’s and 
vascular disease. 
TABLE 3 Plasma selenium and vitamin E levels in all subjects 
 VD 
(n=40) 
AD (n=20) Control 
(n=40) 
 Selenium (µmol/l) 1.39±0.7* 1.48±0.57* 2.06±0.53 
Vitamin E (µmol/l) 1.63±0.74 1.73±0.86 1.78±0.68 
*significantly different from controls 
 
This study showed that increased triglyceride, LDL- 
cholesterol and decreased HDL-cholesterol concentrations in 
plasma were associated with incidence of VD. In addition, total 
cholesterol concentration appeared to be elevated in VD and AD 
patients compared with control subjects. These findings also 
suggest that hypertriglyceridemia and elevated LDL- cholesterol 
may be among the intermediary mechanisms linking 
hyperlipidemia to VD. This observation is in agreement with some 
studies 8,27 and at variance with others 28. A previous study 
suggested that elevated serum lipids may enhance atherogenesis of 
the extracranial and intracranial arteries causing an increase in 
blood viscosity which in turn decreases cerebral perfusion and 
impair cognitive performance 29. 
To operationalize the diagnosis of dementia for this study, we 
developed a composite variable with a positive diagnosis when 
both a clinical diagnosis of dementia or one of its types were 
documented and the patient had a MMSE score less than 24. This 
cutoff has been shown to improve diagnostic accuracy 30. 
Covariates included age, gender, smoking, alcohol intake, blood 
pressure, medical diagnosis (stroke, hypertension and depression), 
family history of dementia or AD, cholesterol level, LDL- 
cholesterol, HDL-cholesterol and triglyceride. Both of the dementia 
groups were similar in BMI, alcohol intake, fish consumption and 
MMSE score. A limitation of this study is the accuracy of the 
diagnosis of dementia. However, the high rate of concordance 
between clinical diagnosis and cognitive testing result suggest 
accuracy of dementia diagnosis.  
The systolic blood pressure was significantly higher in AD and 
VD patients than in controls while the change in diastolic blood 
pressure was not significant. It is noteworthy that the blood 
pressure values for AD and VD patients (156/89 and 148/85 
respectively) were higher than the cut-off value of 140/85mmHg for 
diagnosis of hypertension 23. In their study on association of 
cognitive function with high blood pressure, hypertension and 
high pulse rate in persons aged 60 years and older, Obisesan et al 31 
reported that optimal blood pressure (120/80mmHg) was 
associated with best cognitive performance and that at age 70 years 
and older, high blood pressure, hypertension and uncontrolled 
blood pressure were independently associated with poorer 
cognitive function than normal blood pressure. It is therefore 
suggested that optimal control of blood pressure may be useful in 
preventing neurocognitive loss in the aging population. The causal 
role of vascular risk factors in different types of dementia has been 
linked to sclerosis of small cerebral arteries and arterioles which is 
considered to be responsible for diffuse periventricular white 
matter abnormalities, which play an important role in the 
development of VD 6. It was hypothesized that high concentrations 
of LDL-cholesterol and low levels of HDL-cholesterol are 
independent risk factors for coronary heart disease and carotid 
artery atherosclerosis 32; this in turn may lead to cognitive 
impairment through cerebral hypoperfusion or embolism 33. HDL-
cholesterol particles have also been reported to play a role in the 
removal of excess cholesterol from the brain by interaction with 
ApoE and heparan sulfate proteoglycans in the subendothelial 
space of cerebral microvessels and this mechanism has been linked 
to low incidence of small-vessel disease 34. 
TABLE 4 Correlation coefficient matrix of parameters in VD 
and AD 
Variables TC TG LDL-C EPA LA 
TC NS 0.395* 0.333* -0.353* -0.333* 
LDL-C NS 0.458** NS NS NS 
EPA -0.353* NS NS NS NS 
TG 0.395* NS 0.458 NS NS 
LA -0.333* NS NS NS NS 
*significant @ p<0.05 level, **p<0.01; NS – not significant 
 
There is increasing scientific interest in the hypothesis that 
very-long-chain n-3 PUFAs, as present in fish or fish oil and 
supplements rich in n-3 fatty acids are beneficial for the 
maintenance of cognitive performance in adults. This hypothesis is 
corroborated by the pattern of erythrocyte fatty acid changes in 
this study which shows that the percentage of DHA and EPA, were 
significantly decreased in VD and AD patients compared to control 
subjects. Several observational studies, conducted among older 
adults reported that participants in those studies with high 
erythrocyte levels of eicosapentanoic acid and  docosahexanoic 
acid - which are the most abundant n-3 PUFAs in erythrocyte - had 
a lower risk of experiencing cognitive decline 24, 35. However others 
have reported no such associations 15, 36. Some of these studies also 
evaluated the association between fish consumption and cognitive 
performance and reported a lower incidence of AD 37 or a trend 
toward a lower risk of cognitive decline 38 with increasing fish 
intake. In the present study the average percentage fish intake in 
patients with the dementia subtypes was slightly higher than the 
control subjects. It could be possible that these control subjects 
represent a population of people with relatively unhealthy dietary 
habits, such as inadequate consumption of diets rich in n-3 PUFAs.  
There were no significant differences in erythrocyte levels of 
DHA and EPA in vascular dementia as compared to those in 
Alzheimer’s disease patients probably suggesting a possible 
relationship between n-3 PUFAs and low cognitive function 
irrespective of the subtypes of dementia. This is more likely as both 
VD and AD patients studied scored less than 24 points on the 
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MMSE scale. Dietary n-3 PUFAs had been shown to improve brain 
functioning in animal studies and it was hypothesized that dietary 
intake of n-3 fatty acids and weekly consumption of fish may 
reduce the risk of incident Alzheimer’s disease 37.  Nevertheless, the 
findings in this present study are in line with earlier report by 
Heude et al 24 which showed that lower proportions of n-3 PUFAs 
in erythrocytes are associated with a higher risk of cognitive 
decline. Hence, there is the possibility that a more detailed 
cognitive assessment in a larger population may show significant 
associations in fish consumption and cognitive impairment in this 
community. 
A suggested mechanism for the cardio-protective effect of n-3 
fatty acids focused on their influence on eicosanoid metabolism, 
inflammation, beta oxidation, endothelial dysfunction, cytokine 
growth factors, and gene expression of adhesion molecules 39. 
Cerebrovascular disease might play a role in vascular dementia 34,6. 
N-3 fatty acids are also neuroprotective by suppressing the 
synthesis and release of interleukins and TNF-alpha (which is 
neurotoxic) and modulation of hypothalamic-pituitary-adrenal 
anti-inflammatory responses in the nervous system 39.This shows a 
close association between the central nervous system and dietary 
n-3 fatty acids. High concentrations of DHA and EPA are 
associated with cardiovascular benefit. Trials showed reductions in 
cardiovascular events of 19-45% in subjects receiving n-3 fatty acid 
supplementation containing EPA and DHA. Patients with 
hypertriglyceridemia can also benefit from treatment with 3-4g 
daily intake of DHA and EPA 40. Previous literature from this 
community emphasized or studied the incidence and risk factors of 
VD and AD. With this study, erythrocyte PUFAs, total plasma 
lipid profile, selenium and vitamin E were all determined in the 
two groups of neurodegenerative disorders.  Low level of plasma 
selenium was a constant feature in VD and AD patients but not in 
control subjects. 
Although the slight decrease in plasma values of vitamin E 
observed in patients in comparison with controls in this study was 
not significantly different, low levels of this vitamin may still 
undoubtedly play an important role in the occurrence of these 
neurodegenerative disorders. Several studies found that low intake 
and reduced serum vitamin E was associated with higher risks of 
AD and vascular dementia 41,42 and that Alzheimer’ disease patients 
on vitamin E supplement survived longer than those not getting 
supplements 43. It could be deduced from results obtained in this 
study that vitamin E is unlikely to be responsible for the severity 
and progression of VD and AD among Nigerian Africans when 
compared with the white populations of the developed countries 
41,42. 
Results from this case-control study showed that low levels of 
omega-3 fatty acids and selenium were strongly associated with 
the occurrence of dementia in the elderly Nigerian population 
among whom there is lack of awareness on the benefits of adequate 
consumption of fatty cold water fish that are rich sources of 
eicosapentanoic and docosahexanoic acids known to alleviate 
neurodegeneration. A prospective study investigating the effect of 
omega-3 fatty acids and antioxidant vitamins on pathogenesis of 
dementia in the elderly would shed more light on the observed 
associations. 
Acknowledgements The authors appreciate the technical assistance and 
cooperation of the staff of the Ibadan Dementia Project, University College 
Hospital, Ibadan, Nigeria. 
REFERENCES 
1. Johnson EJ, Schaefer EJ: Potential role of dietary n-3 fatty acids 
in prevention of dementia and macular degeneration. Am J Clin 
Nutr 2006; 83: S1494-1498S. 
2. Ogunniyi A, Hall KS, Gureje O et al: Risk factors for incident 
Alzheimer’s disease in African Americans and Yoruba. Metab 
Brain Dis 2006; 21:235- 2450.  
3. Hendrie HC, Ogunniyi A, Hall KS et al:  Incidence of dementia 
and Alzheimer’s disease in 2 communities: Yorubas residing in 
Nigeria, and African Americans residing in Indianapolis, 
Indiana. JAMA 2001; 285:739-747.  
4. Dullemeijer C, Durga J, Brouwer IA et al: N-3 fatty acids 
proportions in plasma and cognitive performance in older 
adults. American Journal ofc Clinical Nutrition   2007; 86:1479-1485.  
5. Kalmijn S, van Bostel MP, Ocke M et al: Dietary intake of fatty 
acids and fish in relation to cognitive performance at middle 
age. Neurology 2004; 62:275-280.  
6. Reitz C; Tang M; Luchsinger J et al: Relation of Plasma Lipids 
to Alzheimer’s disease and Vascular Dementia. Arch Neurol 
2004; 61: 705-14. 
7. Helsalmi S: Molecular genetics of Alzheimer’s disease with 
Special Emphasis on Presenilin, Amyloid Beta Precursor 
Protein and Apolipoprotein E Genes.Doctoral Dissertation 
presented at Faculty of Medicine, University of Kuopio. 1999; 
No 44. 
8. Moroney JT; Tang MX; Berglund L et al: Low-Density 
Lipoprotein Cholesterol and the Risk of Dementia with Stroke. 
JAMA 1999; 282:254-60.  
9. Sinclair AJ, Barnett H, Lunec J: Free Radical and Antioxidant 
System in Health and Disease. J Applied Med 1991; 7: 409-17. 
10. Markesbery WR: Oxidative alteration in neurodegenerative 
disease. In: Pathogenesis of neurodegenerative disorders. M.P. 
Mattson (ed). Totowa, NJ: Humana Press., 2001; 21-51. 
11. Keller J:  Evidence of increased oxidative damage in subjects 
with mild cognitive impairment. Neurology 2005; 64: 1152-6. 
12.  Sahnoun Z, Jamoussi K, Zeghal KM: Free radicals and 
antioxidants: human physiology, pathology and therapeutic 
aspects. Therapie 1997; 52:251-270. 
13. Vatassey GT:  Vitamin E and other endogenous antioxidants in 
Central Nervous System. Geriatrics 1998; 53: S25-27. 
14. Meydani M, Macauley JB, Blumberg JB: Effect of dietary 
vitamin E and selenium on susceptibility of brain regions to 
lipid peroxidation. Lipids 1988; 23: 405-409. 
15. Engelhart MJ, Geerlings MI, Ruitenberg A et al: Dietary intake 
of antioxidants   and risk of Alzheimer’s disease. JAMA 2002; 
287:3223-3229. 
16. Morris MC: Dietary intake of antioxidant nutrients and the 
risk of incident Alzheimer’s disease in a biracial community 
study. JAMA 2002; 287: 3230-3237. 
17. Neve JJ: Selenium as risk factors for cardiovascular disease. 
Cardiovasc Risk 1996; 3: 42-47. 
18. Shaefer EJ: Lipoproteins, nutrition and heart disease. Am J Clin 
Nutr 2004; 75:191-212. 
Ayelagbe et al. Dyslipidemia, fatty acids and selenium in dementia Biokemistri 23(3):118-123 
123 
19. Clausen J: Dementia syndromes and lipid metabolism. Acta 
Neurol Scand 1984; 70: 345-55.  
20. Roman, GC, Tatenichi TK, Erkinjuntti T et al: Vascular 
dementia: diagnostic criteria for research studies. Report of the 
NINDS-AIREN international workshop.   Neurology 1993; 43: 
250-60. 
21. McKhann, G. Drachman D, Folstein M et al: Mental and 
clinical diagnosis of Alzheimer’s disease: report of the 
NINCDS-ADRDA Work Group under the auspices of the 
Department of Health and Human Services Task Force onv 
Alzheimer’s disease. Neurology 1984; 34: 939-44. 
22. Finckh B, Kontush A, Commentz J et al: High-performance 
liquid Chromatography-coulometric electrochemical detection 
of ubiquinol-10, ubiquinone – 10, carotenoids, and tocopherols 
in neonatal plasma. Methods Enzymol 1999; 299: 341-348. 
23. World Health Organization – International Society of 
Hypertension guidelines for the management of hypertension.  J 
Hypertens 1999; 17: 151-183. 
24. Heude B, Ducimetiere P, Berr C: Cognitive decline and fatty 
acid composition of erythrocyte membranes: the EVA Study. 
Am J Clin Nutr 2003; 77: 803-808. 
25. Morris MC: Docosahexanoic acid and Alzheimer’s disease. Arch 
Neurol 2006; 63:1527- 1528. 
26. Pasquier F, Henon H, Leys D.  Risk factor and mechanisms of 
post stroke dementia (review). Revue Neurologique 1999; 155(a): 
749-753. 
27. Kuo YM, Emmerling MR, Bisgaier CL et al.  Elevated Low-
Density Lipoprotein in Alzheimer’s disease correlates with 
brain Aϐ 1-42 levels. Biochem Biophys Res Commun 1998; 252:711-
715.  
28. Scacchi R, De Bernadi L, Mantuano E et al.  DNA 
polymorphism of apolipoprotein B and angiotensin 1-
converting enzyme genes and relationships with lipid levels in 
Italian patients with vascular dementia or Alzheimer’s disease. 
Dement Geriatr Cogn Disord 1998; 9: 186-190.  
29. Rogers RL, Meyer JS, McClintic K et al.  Reducing 
hypertriglyceridemia in elderly patients with cerebrovascular 
disease stabilizes or improves cognition and cerebral perfusion. 
J Vasc Dis 1989; 8: 260-269. 
30. American Psychiatric Association. Diagnostic and Statistical 
Manual of Mental Disorders (DSMMD) Fourth edition, Revised. 
Washington, DC: American Psychiatric Association 1994. 
31. Obisesan TO, Obisesan OA, Martins S et al.  High blood 
pressure, hypertension and   high pulse pressure are associated 
with cognitive function in persons aged 60 and older: The 3rd 
National Health and Nutrition Examination Survey. J Am 
Geriatr Soc 2008; 56: 501-509. 
32. Sharrett AR, Patsch W, Sorlie PD et al: Associations of 
lipoprotein cholesterols, apolipoprotein A-1 and B, and 
triglyceride with carotid atherosclerosis and coronary heart 
disease: The Atherosclerosis Risk in Communities Study. 
Arterioscler Thromb Vasc Biol 1994; 14:1098-1104. 
33. Breteler MMB, Claus JJ, Grobbee DE et al. Cardiovascular 
disease and distribution of cognitive function in elderly people: 
The Rotherdam Study. BMJ 1994; 308:1604-1608. 
34. Zuliani G, Ble A, Zanca R et al. Lipoprotein profile in older 
patients with vascular dementia and Alzheimer’s disease. BMC 
Geriatr 2001; 1: 1471-1475. 
35. Conquer JA, Tierney MC, Zecevic J et al. Fatty acid analysis of   
blood plasma of patients with Alzheimer’s disease, other types 
of dementia, and cognitive impairment. Lipids 2000; 35:130. 
36. Laurin D, Verreault R, Lindsay J et al.  Omega-3 fatty acids and 
risk of cognitive impairment and dementia. J Alzheimers Dis 
2003; 5: 315-22.  
37. Morris MC, Evans DA, Bienias JL et al.  Consumption of fish 
and n-3 fatty acids and risk of incident of Alzheimer’s disease. 
Archives of Neurology 2003; 60: 940-946. 
38. Kalmijn S; Launer LJ, Ott A et al.  Dietary fat intake and the 
risk of incident in the Rotterdam Study. Ann Neurol 1997; 42: 
776-82.  
39. Das UN.  Beneficial effect(s) of n-3 fatty acids in cardiovascular 
diseases: but, why and how? Prostaglandin Leukot Essent Fatty 
Acids 2000; 63:351-362.  
40. O’Keefe J.  Cardiovascular Benefits of Omega-3 Fatty Acids 
Reviewed. Mayo Clinic (March 12) Science Daily 2008.  
41. Grundman M. 2000. Vitamin E and Alzheimer’s disease: the 
basis for additional clinical trials. American Journal of Clinical 
Nutrition 2000; 71: 630S-636S.  
42. Rygllewicz D, Rodo M, Kunicki PK et al. Plasma antioxidant 
activity and vascular dementia. J Neurol Sci 2002; 203-204: 195-
197.  
43. Lombard D, Khalsa DS.  Alzheimer’s disease and Nutrition. 
“Nature’s Medicines” from Rodale books (Online) April, 2009; 
www.pspinformation.com/disease/alzheimers-   
nutrition.shtml. 
44. Pandey M, Sharma L, Singh S, Shukla V. Erythrocyte membrane 
fatty acids profile and saturation index in gallbladder 
carcinogenesis: a case-control study. World Journal of Surgical 
Oncology 2003; 1:5. 
